Renal Pharmacology

Correct Answer

B — Canagliflozin

Rationale

Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that blocks glucose-coupled sodium reabsorption in the proximal convoluted tubule. Lisinopril is an angiotensin converting enzyme inhibitor. Epoetin alfa is an erythropoiesis-stimulating agent. Cinacalcet is a calcimimetic.

Correct Answer

D — Epoetin alfa

Rationale

Epoetin alfa is an erythropoiesis-stimulating agent structurally identical to endogenous erythropoietin, used to treat anemia of chronic kidney disease. Canagliflozin is a sodium-glucose cotransporter 2 inhibitor. Sevelamer is a phosphate binder. Cinacalcet is a calcimimetic.

Correct Answer

A — Sevelamer

Rationale

Sevelamer is a non-calcium, non-metal polymer phosphate binder that avoids calcium loading and also lowers low-density lipoprotein cholesterol. Calcium carbonate and calcium acetate are calcium-based binders. Lanthanum carbonate is a non-calcium metal-based binder.

Correct Answer

C — Cinacalcet

Rationale

Cinacalcet is classified as a calcimimetic — an agent that allosterically activates the calcium-sensing receptor on parathyroid chief cells, increasing its sensitivity to extracellular calcium and reducing parathyroid hormone secretion. Calcitriol is an active vitamin D analog. Sevelamer is a phosphate binder. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor.

Correct Answer

A — Roxadustat

Rationale

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase domain inhibitor — the first member of a new oral drug class for chronic kidney disease anemia. By blocking prolyl hydroxylase domain enzymes, it stabilizes hypoxia-inducible factor 1-alpha and stimulates endogenous erythropoietin production. Epoetin alfa is a direct erythropoiesis-stimulating agent (exogenous erythropoietin). Cinacalcet is a calcimimetic. Canagliflozin is a sodium-glucose cotransporter 2 inhibitor.

Correct Answer

D — Metformin

Rationale

Metformin is classified as a biguanide antidiabetic agent. It is entirely renally excreted by tubular secretion and accumulates in chronic kidney disease, which is why it requires dose reduction at low glomerular filtration rates and is held below an estimated glomerular filtration rate of 30 milliliters per minute. Canagliflozin is a sodium-glucose cotransporter 2 inhibitor. Epoetin alfa is an erythropoiesis-stimulating agent. Cinacalcet is a calcimimetic.

Correct Answer

C — Blockade of proximal tubular sodium reabsorption restores sodium delivery to the macula densa, triggering afferent arteriolar constriction via tubuloglomerular feedback and reducing intraglomerular pressure

Rationale

In chronic kidney disease, surviving nephrons hyperfiltrate and reabsorb excess sodium in the proximal tubule, reducing sodium delivery to the macula densa. The macula densa interprets this as inadequate filtration and dilates the afferent arteriole — a compensatory response that raises intraglomerular pressure and accelerates nephron loss. Sodium-glucose cotransporter 2 inhibitors block glucose-coupled sodium reabsorption in the proximal tubule, restoring sodium delivery to the macula densa and triggering afferent arteriolar constriction via tubuloglomerular feedback. This reduces intraglomerular pressure regardless of glycemic control, explaining the renoprotective effect in both diabetic and non-diabetic chronic kidney disease.

Correct Answer

A — Efferent arteriolar dilation reduces intraglomerular capillary pressure, decreasing the hydraulic force driving protein across the filtration barrier

Rationale

Angiotensin II preferentially constricts the efferent arteriole, raising intraglomerular capillary pressure and driving protein across the filtration barrier into the tubular lumen. Angiotensin converting enzyme inhibitors block angiotensin II production, dilating the efferent arteriole and reducing intraglomerular pressure. This decreases the hydraulic force driving protein filtration, reducing proteinuria through a hemodynamic mechanism independent of any effect on systemic blood pressure. The acute creatinine rise in this patient reflects the expected fall in glomerular filtration rate from reduced hydraulic filtration pressure — not renal injury — and a rise up to 30% above baseline is acceptable and expected.

Correct Answer

D — Metformin accumulates in chronic kidney disease and inhibits hepatic lactate clearance, raising plasma lactate levels

Rationale

Metformin is entirely renally excreted by tubular secretion and accumulates in direct proportion to the decline in glomerular filtration rate. Accumulated metformin inhibits hepatic lactate clearance — the liver's capacity to convert lactate back to glucose — raising plasma lactate concentrations. The result is metformin-associated lactic acidosis, a rare but potentially fatal complication. This is why metformin is held when the estimated glomerular filtration rate falls below 30 milliliters per minute and why it is withheld before iodinated contrast procedures that could acutely reduce renal function.

Correct Answer

B — Erythropoiesis-stimulating agents drive accelerated red cell production that depletes iron stores faster than mobilization can supply iron to the bone marrow, producing functional iron deficiency

Rationale

Erythropoiesis-stimulating agents stimulate rapid red blood cell production, which consumes iron at a rate that exceeds the body's capacity to mobilize it from stores to the bone marrow. The result is functional iron deficiency — a state in which total body iron may be adequate but delivery to the bone marrow is insufficient to support the accelerated erythropoiesis. Iron is an absolute co-requirement for erythropoiesis-stimulating agent therapy, and hyporesponsiveness is most commonly caused by iron deficiency. Intravenous iron is preferred over oral supplementation in dialysis patients because chronic inflammation raises hepcidin, which blocks iron absorption from the gut.

Correct Answer

C — Clinical trials demonstrated that targeting hemoglobin above 11 to 12 g/dL with erythropoiesis-stimulating agents increases the risk of stroke, myocardial infarction, thrombosis, and death

Rationale

The CHOIR and TREAT trials both demonstrated harm from higher hemoglobin targets in chronic kidney disease patients treated with erythropoiesis-stimulating agents. Targeting hemoglobin above 11 to 12 grams per deciliter was associated with increased rates of stroke, myocardial infarction, venous thromboembolism, and all-cause mortality compared with lower targets. The mechanism is not fully established but likely involves prothrombotic effects of supraphysiological erythropoiesis-stimulating agent exposure rather than the hemoglobin level itself. Current guidelines recommend maintaining hemoglobin between 10 and 11.5 grams per deciliter using the lowest effective dose.

Correct Answer

A — Cinacalcet allosterically activates the calcium-sensing receptor on parathyroid chief cells, increasing the receptor's sensitivity to extracellular calcium and reducing parathyroid hormone secretion

Rationale

Cinacalcet is a calcimimetic that allosterically activates the calcium-sensing receptor on parathyroid chief cells, making it more sensitive to ambient extracellular calcium. The parathyroid gland is thereby tricked into sensing higher calcium than is actually present and reduces parathyroid hormone secretion. Because cinacalcet acts at the parathyroid receptor without increasing intestinal calcium absorption or releasing calcium from bone, it lowers parathyroid hormone without raising serum calcium — in contrast to active vitamin D analogs, which suppress parathyroid hormone but increase intestinal calcium absorption and can worsen hypercalcemia.

Correct Answer

D — Phosphate binders must be present in the gastrointestinal tract at the same time as dietary phosphate to bind and prevent its absorption

Rationale

Phosphate binders act entirely within the gastrointestinal tract by physically binding dietary phosphate before it can be absorbed. They are not absorbed into the systemic circulation. For this mechanism to work, the binder must be present in the gut simultaneously with the dietary phosphate load from a meal. Taking a phosphate binder away from meals results in no dietary phosphate being present for it to bind, rendering the dose ineffective. This pharmacokinetic rationale — luminal action requiring co-ingestion with substrate — applies to all phosphate binders regardless of whether they are calcium-based, metal-based, or polymer-based.

Correct Answer

B — The ONTARGET trial showed the combination provides no additional renoprotection over either agent alone while substantially increasing the risk of hyperkalemia and acute kidney injury

Rationale

The ONTARGET trial directly compared telmisartan, ramipril, and their combination in high-risk vascular patients and definitively established that dual renin-angiotensin-aldosterone system blockade does not provide additional renoprotection over either agent alone. Instead, the combination substantially increased the risk of hyperkalemia, hypotension, and acute kidney injury. Current guidelines therefore recommend one agent from either the angiotensin converting enzyme inhibitor or angiotensin receptor blocker class — not both — for renoprotection in chronic kidney disease.

Correct Answer

C — Canagliflozin restores sodium delivery to the macula densa, triggering afferent arteriolar constriction via tubuloglomerular feedback and reducing intraglomerular pressure through a mechanism independent of renin-angiotensin-aldosterone system blockade

Rationale

Lisinopril reduces intraglomerular pressure by dilating the efferent arteriole through angiotensin II blockade. Canagliflozin reduces intraglomerular pressure through a complementary and independent pathway: by blocking sodium-glucose cotransporter 2, it increases sodium delivery to the macula densa, which triggers afferent arteriolar constriction via tubuloglomerular feedback. Because these two mechanisms act at different points in the pressure-regulating circuit, their combination provides additive intraglomerular pressure reduction without requiring glycemic improvement. The CREDENCE trial confirmed this benefit in patients with type 2 diabetes and chronic kidney disease already receiving renin-angiotensin-aldosterone system blockade.

Correct Answer

A — Epoetin alfa has driven accelerated erythropoiesis that depletes available iron faster than it can be mobilized to the bone marrow, producing functional iron deficiency that limits red cell production

Rationale

This patient's low ferritin and transferrin saturation confirm iron-deficient erythropoiesis. Erythropoiesis-stimulating agents accelerate red cell production and rapidly consume the iron available for hemoglobin synthesis. When mobilization of iron from stores cannot keep pace with demand, functional iron deficiency develops and limits the erythropoietic response regardless of how much erythropoiesis-stimulating agent is given. This is the most common cause of erythropoiesis-stimulating agent hyporesponsiveness. Intravenous iron supplementation is required before or alongside erythropoiesis-stimulating agent therapy to restore the erythropoietic response.

Correct Answer

D — Calcimimetics, which allosterically activate the calcium-sensing receptor on parathyroid chief cells to reduce parathyroid hormone secretion without increasing intestinal calcium absorption

Rationale

Cinacalcet, a calcimimetic, allosterically activates the calcium-sensing receptor on parathyroid chief cells, increasing the receptor's sensitivity to ambient calcium and reducing parathyroid hormone secretion. Unlike active vitamin D analogs, which suppress parathyroid hormone by increasing intestinal calcium absorption and can worsen hypercalcemia, cinacalcet acts directly at the parathyroid gland without raising serum calcium. This makes calcimimetics the preferred choice when secondary hyperparathyroidism is complicated by hypercalcemia and active vitamin D analogs cannot safely be used.

Correct Answer

B — Ramipril dilates the efferent arteriole, reducing intraglomerular hydraulic pressure and the filtration rate; this expected hemodynamic effect is not renal injury

Rationale

Angiotensin II preferentially constricts the efferent arteriole to maintain intraglomerular pressure. When ramipril blocks angiotensin II production, the efferent arteriole dilates and intraglomerular pressure falls. The reduction in hydraulic filtration pressure predictably lowers the glomerular filtration rate and raises serum creatinine. This is an expected hemodynamic consequence of the drug's renoprotective mechanism — not structural renal injury. A creatinine rise up to 30% above baseline within the first weeks of therapy is acceptable and should not prompt drug discontinuation. A rise beyond 30%, or occurring without volume depletion, warrants investigation for bilateral renal artery stenosis.